Trial Profile

A phase 2 pilot study of AlloStem CELZ-201 in late stage Type 2 Diabetes patients

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 18 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Allogenic cellular therapy Creative Medical Technology (Primary)
Indications Type 2 diabetes mellitus
Focus Therapeutic Use

Most Recent Events

18 Feb 2025 New trial record
11 Feb 2025 According to a Creative Medical Technology Holdings media release, the company plans to advance the development of AlloStem (CELZ-201) for the treatment of late-stage Type 2 Diabetes and explore other potential applications of this therapy to expand the Companys pipeline.
11 Feb 2025 Results(n=20) evaluating safety and efficacy of AlloStem (CELZ-201) presented in the Creative Medical Technology Holdings media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com